FDA Expands Vutrisiran Indication to ATTR-Cardiomyopathy
The US Food and Drug Administration (FDA) has approved a supplemental new drug application for vutrisiran for the treatment of wild-type or hereditary transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) to reduce cardiovascular death, hospitalization, and urgent heart failure visits. ATTR-CM is a rapidly progressive and ultimately fatal disease affecting roughly 15src,srcsrcsrc Americans…
The US Food and Drug Administration (FDA) has approved a supplemental new drug application for vutrisiran for the treatment of wild-type or hereditary transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) to reduce cardiovascular death, hospitalization, and urgent heart failure visits. ATTR-CM is a rapidly progressive and ultimately fatal disease affecting roughly 15src,srcsrcsrc Americans…
Read More
About Author
